Blue Earth will be sharing anonymized clinical data from its Phase 3 Lighthouse trial involving the use of PET imaging agent Posluma.

A team of experts determined that correlating masses initially detected on MRI are significantly more likely to result in a cancer diagnosis than other common findings. 

Comparing only imaging centers that operated both quarters, MRI volumes increased 10% compared to Q1 of 2023 while PET/CT was up more than 15%. 

Staffers with the Centers for Medicare & Medicaid Services were "attentive to the discussion and requested supporting documentation," ACR reported. 

Founded in 2020, the Paris-based firm offers products to aid physicians in assessing and documenting OB/GYN scans. 

The agent was found to be better than standard CT imaging for patients with clear cell renal cell cancer.

The model incorporates specific data from MRI exams with patient risk factors to predict whether a person is likely to develop clinically significant prostate cancer.

Penn Medicine experts conducted two randomized clinical trials, with women receiving text message reminders, bulk orders or letters endorsed by their PCP.